NewData from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit withPXT3003 inPatients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New data from the ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results